Table 1.
Patient characteristics
| Demographic and clinical characteristics | N | % |
|---|---|---|
| Sex | ||
| Male | 3 | 37.5 |
| Female | 5 | 62.5 |
| Age at diagnosis, median (range) | 39 (15–64) | |
| Age at enrollment, median (range) | 42 (18–65) | |
| Body weight in kg, median (range) | 82.8 (59.8–125.9) | |
| Performance status | ||
| 0 | 7 | 87.5 |
| 2 | 1 | 12.5 |
| Tumor stage at initial diagnosis | ||
| IV | 8 | 100 |
| Site of tumor at enrollment | ||
| Primary adrenal gland | 1 | 12.5 |
| Adrenal bed (local recurrence) | 7 | 87.5 |
| Regional intra-abdominal recurrence1 | 1 | 12.5 |
| Lung metastases | 8 | 100 |
| Liver metastases | 4 | 50 |
| Bone metastases | 1 | 12.5 |
| Prior treatment | ||
| Surgery2 | 7 | 87.5 |
| Radiotherapy | 2 | 25 |
| Chemotherapy | 8 | 100 |
| Mitotane monotherapy | 7 | 87.5 |
| Etoposide, doxorubicin, cisplatin, and mitotane | 8 | 100 |
| Protease inhibitor3 | 1 | 12.5 |
| Abraxane | 1 | 12.5 |
1
A single patient was found to have metastatic disease to the intra-abdominal mesentery.
2
Prior surgeries include primary resection of adrenocortical carcinoma, metastectomy, and debulking procedures.
3
A single patient underwent treatment with proteasome inhibitors, bortezomib, and carfilzomib.